# Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors

> **NCT01940601** · PHASE2 · WITHDRAWN · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.**

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Balugrastim
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT01940601
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-09
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01940601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01940601, "Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01940601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*